drugset / Trial / NCT02135536
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
Phase 2
Completed
36 enrolled
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
Timeline
- Start
- 2014-05
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldafermin | Protein / enzyme biologic | — | — |